SpringWorks Therapeutics (SWTX) announced that the Company anticipates the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, will adopt an opinion on the marketing authorization application, MAA, for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- BofA moves to No Rating on SpringWorks Therapeutics
- M&A News: Merck KGaA to Buy SpringWorks for $3.5B to Boost Oncology Business
- Merck KGaA confirms late-stage talks to acquire SpringWorks for $47 per share
- Merck KGaA near $47 per share deal to buy SpringWorks Therapeutics, WSJ says
- SpringWorks EU approval would enhance strategic value, says Evercore